ALX Oncology Holdings Inc (ALXO)
1.29
+0.08
(+6.61%)
USD |
NASDAQ |
Nov 21, 16:00
1.29
0.00 (0.00%)
After-Hours: 20:00
ALX Oncology Holdings Enterprise Value: -70.70M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -70.70M |
| November 20, 2024 | -74.92M |
| November 19, 2024 | -73.86M |
| November 18, 2024 | -74.39M |
| November 15, 2024 | -70.70M |
| November 14, 2024 | -68.59M |
| November 13, 2024 | -68.06M |
| November 12, 2024 | -68.06M |
| November 11, 2024 | -60.68M |
| November 08, 2024 | -62.26M |
| November 07, 2024 | -59.10M |
| November 06, 2024 | -58.04M |
| November 05, 2024 | -58.57M |
| November 04, 2024 | -60.15M |
| November 01, 2024 | -62.26M |
| October 31, 2024 | -63.32M |
| October 30, 2024 | -65.95M |
| October 29, 2024 | -64.90M |
| October 28, 2024 | -61.73M |
| October 25, 2024 | -61.21M |
| October 24, 2024 | -62.00M |
| October 23, 2024 | -51.19M |
| October 22, 2024 | -59.62M |
| October 21, 2024 | -59.62M |
| October 18, 2024 | -60.68M |
| Date | Value |
|---|---|
| October 17, 2024 | -59.10M |
| October 16, 2024 | -56.46M |
| October 15, 2024 | -56.46M |
| October 14, 2024 | -56.99M |
| October 11, 2024 | -57.51M |
| October 10, 2024 | -62.79M |
| October 09, 2024 | -53.30M |
| October 08, 2024 | -51.71M |
| October 07, 2024 | -54.88M |
| October 04, 2024 | -50.13M |
| October 03, 2024 | -48.02M |
| October 02, 2024 | -42.22M |
| October 01, 2024 | -40.64M |
| September 30, 2024 | -42.75M |
| September 27, 2024 | -43.19M |
| September 26, 2024 | -48.46M |
| September 25, 2024 | -51.62M |
| September 24, 2024 | -44.24M |
| September 23, 2024 | -42.14M |
| September 20, 2024 | -37.92M |
| September 19, 2024 | -32.66M |
| September 18, 2024 | -34.24M |
| September 17, 2024 | -32.13M |
| September 16, 2024 | -32.13M |
| September 13, 2024 | -30.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-76.99M
Minimum
Jun 16 2022
3.912B
Maximum
Dec 10 2020
792.60M
Average
297.39M
Median
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Neurocrine Biosciences Inc | 11.43B |
| Eton Pharmaceuticals Inc | 261.60M |
| Verve Therapeutics Inc | -150.47M |
| Immuneering Corp | 14.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.71M |
| Total Expenses (Quarterly) | 32.57M |
| EPS Diluted (Quarterly) | -0.58 |
| Earnings Yield | -230.2% |
| Normalized Earnings Yield | -81.55 |